Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins – BIO’s Greenwood
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
You may also be interested in...
Rebate Reporting Law May Provide Timely Trigger For US Pricing Debate – In 2023
Newly enacted requirement for US health plans to report granular drug price and rebating data to the government suggests that the great rebate debate of 2017-2020 won’t be over for long. The first public release of aggregated data will likely come in 2023 – and that might be when Congress is ready to take up drug pricing again.
Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill
Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry.
MedPAC To The Rescue? How US Policy Advisors Could Save The Drug Industry
The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.